MedicaidCoverageMedium impact
KMAP BULLETIN: Preferred Drug List Update February 2026
Kansas Medicaid (KanCare)·KS·Pharmacy
Effective date
Feb 1, 2026
We identified it
Jun 21, 2026
Summary
KMAP updated their preferred drug list effective February 1, 2026, moving several medications including Desloratadine, Arbli, Vyscoxa, and others to non-preferred status while making one version of Imuldosa preferred. This affects prior authorization requirements and patient cost-sharing for Kansas Medicaid patients.
Action Required
Before February 1, 2026: Billing and clinical teams must update medication ordering protocols to reflect new preferred drug list changes for Kansas Medicaid patients. Review patient medication lists for affected drugs (Desloratadine oral solution, Arbli, Vyscoxa, Imuldosa from Labeler 51407, Chlorzoxazone 250mg, Kirsty insulin, Coxanto, Relafen DS, Javadin) and consider switching to preferred alternatives. Update pharmacy systems and provider alerts. Non-preferred medications may require prior authorization or result in higher patient costs.